MA34457B1 - Combinaison d'un composé glyt1 avec des agents antipsychotiques - Google Patents

Combinaison d'un composé glyt1 avec des agents antipsychotiques

Info

Publication number
MA34457B1
MA34457B1 MA35645A MA35645A MA34457B1 MA 34457 B1 MA34457 B1 MA 34457B1 MA 35645 A MA35645 A MA 35645A MA 35645 A MA35645 A MA 35645A MA 34457 B1 MA34457 B1 MA 34457B1
Authority
MA
Morocco
Prior art keywords
combination
glyt1
compound
antipsychotic agents
schizophrenia
Prior art date
Application number
MA35645A
Other languages
English (en)
Inventor
Joseph G Wettstein
Daniela Alberati
Jean-Luc Moreau
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34457(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34457B1 publication Critical patent/MA34457B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une association pharmaceutique combinant un inhibiteur du transporteur de la glycine (GlyT1) et un médicament antipsychotique atypique, ladite association pouvant être utilisée pour traiter les symptômes positifs et négatifs de la schizophrénie.
MA35645A 2010-08-09 2011-08-05 Combinaison d'un composé glyt1 avec des agents antipsychotiques MA34457B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10172316 2010-08-09
PCT/EP2011/063533 WO2012019970A1 (fr) 2010-08-09 2011-08-05 Combinaison d'un composé glyt1 avec des agents antipsychotiques

Publications (1)

Publication Number Publication Date
MA34457B1 true MA34457B1 (fr) 2013-08-01

Family

ID=44512856

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35645A MA34457B1 (fr) 2010-08-09 2011-08-05 Combinaison d'un composé glyt1 avec des agents antipsychotiques

Country Status (29)

Country Link
US (1) US20120035156A1 (fr)
EP (1) EP2603219B1 (fr)
JP (1) JP2013533297A (fr)
KR (1) KR101455947B1 (fr)
CN (1) CN103068388A (fr)
AR (1) AR084401A1 (fr)
AU (1) AU2011288536B2 (fr)
BR (1) BR112013003068A2 (fr)
CA (1) CA2803656A1 (fr)
CL (1) CL2013000378A1 (fr)
CR (1) CR20130027A (fr)
CY (1) CY1115886T1 (fr)
DK (1) DK2603219T3 (fr)
EA (1) EA201291477A1 (fr)
EC (1) ECSP13012431A (fr)
ES (1) ES2521596T3 (fr)
HR (1) HRP20141199T1 (fr)
MA (1) MA34457B1 (fr)
MX (1) MX2013001166A (fr)
NZ (1) NZ604891A (fr)
PE (1) PE20131100A1 (fr)
PH (1) PH12013500078A1 (fr)
PL (1) PL2603219T3 (fr)
PT (1) PT2603219E (fr)
SG (1) SG187108A1 (fr)
SI (1) SI2603219T1 (fr)
TW (1) TW201211019A (fr)
WO (1) WO2012019970A1 (fr)
ZA (1) ZA201300434B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
FI3932932T3 (fi) 2013-03-13 2025-10-15 Sage Therapeutics Inc Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
MX2016006742A (es) * 2013-12-03 2016-08-12 Hoffmann La Roche Composicion farmaceutica.
SG10202102125SA (en) * 2014-04-30 2021-04-29 Yufeng Tseng Use of known compounds as d-amino acid oxidase inhibitors
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
BR112017007053A2 (pt) * 2014-10-07 2018-06-19 Sage Therapeutics Inc compostos neuroativos e métodos de utilização deste composto.
PT3319611T (pt) 2015-07-06 2021-04-22 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
DK3812392T3 (da) 2015-07-06 2025-07-21 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
WO2017007832A1 (fr) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxystérols et leurs procédés d'utilisation
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (fr) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxystérols et méthodes d'utilisation associées
WO2018009867A1 (fr) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxystérols et leurs méthodes d'utilisation
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
DK3529257T3 (da) 2016-10-18 2023-08-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
BR112020009310A2 (pt) * 2017-11-14 2020-10-13 Sk Biopharmaceuticals Co., Ltd. combinação e composição farmacêutica para a prevenção, alívio ou tratamento da esquizofrenia.
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544820A (en) * 2003-08-11 2009-02-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
WO2006000222A2 (fr) * 2004-06-24 2006-01-05 H. Lundbeck A/S Combinaison d'un antipsychotique et d'un inhibiteur de type 1 transporteur de glycine pour le traitement de la schizophrenie
MX2007012463A (es) * 2005-04-08 2007-11-07 Pfizer Prod Inc Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i.
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
UA94615C2 (uk) * 2006-06-28 2011-05-25 Амген Інк. Інгібітори транспортера-1 гліцину

Also Published As

Publication number Publication date
US20120035156A1 (en) 2012-02-09
WO2012019970A1 (fr) 2012-02-16
PE20131100A1 (es) 2013-09-23
PL2603219T3 (pl) 2015-03-31
SI2603219T1 (sl) 2014-12-31
EA201291477A1 (ru) 2013-06-28
JP2013533297A (ja) 2013-08-22
EP2603219A1 (fr) 2013-06-19
TW201211019A (en) 2012-03-16
PH12013500078A1 (en) 2013-03-11
ECSP13012431A (es) 2013-03-28
PT2603219E (pt) 2014-11-25
SG187108A1 (en) 2013-02-28
AU2011288536B2 (en) 2014-10-09
MX2013001166A (es) 2013-03-22
AR084401A1 (es) 2013-05-15
CY1115886T1 (el) 2017-01-25
NZ604891A (en) 2015-01-30
HRP20141199T1 (hr) 2015-02-13
EP2603219B1 (fr) 2014-09-17
ZA201300434B (en) 2013-09-25
ES2521596T3 (es) 2014-11-13
CR20130027A (es) 2013-03-04
KR101455947B1 (ko) 2014-10-28
BR112013003068A2 (pt) 2016-06-28
KR20130045379A (ko) 2013-05-03
CN103068388A (zh) 2013-04-24
DK2603219T3 (da) 2014-10-13
CL2013000378A1 (es) 2013-05-03
AU2011288536A1 (en) 2013-01-31
CA2803656A1 (fr) 2012-02-16

Similar Documents

Publication Publication Date Title
EA201291477A1 (ru) КОМБИНАЦИЯ СОЕДИНЕНИЙ GlyT1 С АНТИПСИХОТИЧЕСКИМИ СРЕДСТВАМИ
MA37740B2 (fr) Seringue
EA201070786A1 (ru) Бензофуропиримидиноны
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
JO3116B1 (ar) مشتق بيرازولوكينولين كمثبطات ل pde9
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
MX2015011778A (es) Combinacion de farmaco.
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
MY163083A (en) Solid forms of a pharmaceutically active substance
EP2618154A4 (fr) Méthode de détermination de l'efficacité d'un médicament contenant un anticorps comme composant
MA38096B1 (fr) Solutions mydriatiques et anti-inflammatoires stables sans agents de conservation destinees a etre injectees
MA40308A1 (fr) Pyridine-2- amides utiles comme agonistes de cb2
EA201270590A1 (ru) Ингибиторы акт
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
ES2572001T3 (es) Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
MA35043B1 (fr) Formulation pharmaceutique comprenant de l'inositol
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
JO3192B1 (ar) مركب بنزوثيازولون
MA34709B1 (fr) Compositions pharmaceutiques
CY1112501T1 (el) Φαρμακευτικες συνθεσεις περιεχουσες λεφλουνομιδη
MA41311B1 (fr) Peptides antagonistes du cgrp